The EU is positioned on the vaccine from Sanofi is currently in full development. The european Commission said Friday it has booked on behalf of the 27 member States 300 million doses of the vaccine in preparation in the French laboratory. The european executive should not stop there. “Intensive discussions are also underway with other manufacturers.
Read also Covid-19 : a vaccine French tested on humans starting in July
According to Brussels, ” the proposed contract with Sanofi would provide an option to all member States for purchasing the vaccine “. The discussions between the Commission and the laboratory have helped to put in place a framework for the purchase of 300 million doses, if a vaccine is “safe and effective” is developed. “Although we do not know today which vaccine will be most effective in the end, Europe is investing in a diversified portfolio of promising vaccines, based on different types of technologies. This increases our chance of obtaining an effective remedy against the virus, ” explained the president of the Commission, Ursula von der Leyen.
The government welcomes the announcement of the Commission
a Few hours before the announcement, european, Sanofi and the laboratory british GSK have announced that they would receive up to $ 2.1 billion in the United States for the development of their vaccine potential anti-Covid-19, after they have been selected to provide 100 million doses in the united states. The French government welcomed the announcement of the Commission, which ” will enable each member State of the european Union to order on advantageous terms for the vaccine once it has provided sufficient evidence of its effectiveness and lack of side effects “.
Read also BioNTech, in the race to the vaccine, anti-Covid-19
in Mid-June, the european Commission had published a ” strategy for vaccines “. This action plan aims to sign contracts with advance purchase ” with the producers of the vaccines, funded by the instrument for emergency assistance (about 2.4 billion euro) put in place during the crisis. The objective is to” ensure sufficient production of vaccines in the EU ” and ” a sufficient supply of the member States “.
writing will advise you
Sanofi : “The vaccine could be available in the second half of 2021” Vaccine against the Covid-19 : words of guinea pigs Covid-19 : the French in the forefront in the race for the vaccine
